|
Jul 14
|
Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference
|
|
Jul 11
|
Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update
|
|
Jul 11
|
1 Profitable Stock with Solid Fundamentals and 2 to Brush Off
|
|
Jul 10
|
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
|
|
Jul 10
|
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
|
|
Jul 1
|
Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
|
|
Jun 27
|
The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call
|
|
Jun 11
|
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®
|
|
Jun 10
|
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
|
|
Jun 9
|
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
|
|
May 26
|
3 of Wall Street’s Favorite Stocks with Mounting Challenges
|
|
May 23
|
Insiders Pour Millions into These 3 Stocks — Here’s Why They Draw Plaudits Across the Board
|
|
Apr 23
|
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma
|
|
Apr 23
|
Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak
|
|
Apr 23
|
3 Small-Cap Stocks in the Doghouse
|
|
Apr 22
|
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
|
|
Apr 21
|
Jazz Pharmaceuticals Completes Acquisition of Chimerix
|
|
Apr 21
|
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
|
|
Apr 17
|
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
|
|
Apr 17
|
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
|